Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares

Q: At what prices did Anne Lesage sell Pharvaris (PHVS) shares in the Form 4?

The reported sale prices are weighted averages around $35 per share, with ranges from $35.00 up to between $35.30 and $35.86 . The filing notes multiple trades per day and offers to provide detailed price breakdowns upon request.

Q: What were the strike prices of the Pharvaris (PHVS) options exercised by Anne Lesage?

The stock options exercised had strike prices of $8.05 and $2.59 per share. The filing also notes vesting schedules, with 25% vesting on specific dates and the remainder vesting in equal monthly installments over 48 months.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and share sales in Pharvaris common stock. She exercised options to acquire 37,572 shares at strike prices of $8.05 and $2.59 per share, then sold 76,172 shares in open-market transactions at weighted average prices around $35 per share. The filing states these were scheduled transactions under a Rule 10b5-1 trading plan and involved cashless exercise of options. After the transactions, she holds 58,750 shares directly and 93,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls.

Insights

Pre-planned option exercises paired with routine share sales.

The transactions show Anne Lesage exercising Pharvaris stock options at strike prices of $8.05 and $2.59, then selling 76,172 common shares around $35 per share. This is a classic exercise-and-sell pattern converting option value into cash.

Footnotes specify the trades were executed under a Rule 10b5-1 trading plan and via cashless exercises. Such pre-arranged plans reduce the informational value of timing, suggesting these are scheduled liquidity events rather than opportunistic trades.

After these moves, she retains 58,750 shares directly and 93,969 indirectly through GrayMatters Consulting B.V.. The filing does not quantify her stake versus total shares, so the overall ownership impact is hard to gauge from this document alone.

Insider Trade Summary 10b5-1

Net Seller: 76,172 shares ($2,695,452)

Net Sell 16 txns

Insider Lesage Anne

Role Chief Early Development

Sold 76,172 shs ($2.70M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	24,900	$0.00	--
Exercise	Stock Option (Right to Buy)	2,972	$0.00	--
Exercise	Common Stock	2,972	$2.59	$8K
Exercise	Common Stock	24,900	$8.05	$200K
Sale	Common Stock	27,872	$35.4797	$989K
Sale	Common Stock	30,703	$35.4896	$1.09M
Exercise	Stock Option (Right to Buy)	4,200	$0.00	--
Exercise	Stock Option (Right to Buy)	1,400	$0.00	--
Exercise	Stock Option (Right to Buy)	4,100	$0.00	--
Exercise	Common Stock	1,400	$2.59	$4K
Exercise	Common Stock	900	$8.05	$7K
Exercise	Common Stock	4,100	$2.59	$11K
Exercise	Common Stock	4,200	$8.05	$34K
Sale	Common Stock	2,300	$35.1242	$81K
Sale	Common Stock	8,300	$35.0491	$291K
Sale	Common Stock	6,997	$35.0481	$245K

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 shares (Direct, null); Common Stock — 61,722 shares (Direct, null); Common Stock — 93,969 shares (Indirect, By GrayMatters Consulting BVBA)

Footnotes (1)

This is a scheduled exercise and sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. This is a scheduled sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 76,172 shares Options exercised: 37,572 shares Sale price range: $35.00–$35.86/share +3 more

6 metrics

Shares sold 76,172 shares Net shares sold across open-market transactions

Options exercised 37,572 shares Total common shares acquired via option exercises

Sale price range $35.00–$35.86/share Weighted-average sale prices noted in footnotes

Strike prices $8.05 and $2.59/share Exercise prices of stock options converted

Direct holdings after trades 58,750 shares Common stock held directly by Anne Lesage

Indirect holdings after trades 93,969 shares Common stock held via GrayMatters Consulting B.V.

Key Terms

Rule 10b5-1 trading plan, cashless exercise transaction, weighted average sale price, Stock Option (Right to Buy), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise transaction financial

"shares were sold in connection with the exercise of stock options in a cashless exercise transaction"

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting in 1/48 monthly installments financial

"remaining shares vesting in 1/48 monthly installments thereafter"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 07:03 PM Accepted by SEC EDGAR 07/01/2026 - 07:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lesage Anne

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Early Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		M⁽¹⁾		1,400	A	$2.59	57,850	D
Common Stock	06/29/2026		M⁽¹⁾		900	A	$8.05	58,750	D
Common Stock	06/29/2026		M⁽¹⁾		4,100	A	$2.59	56,450	D
Common Stock	06/29/2026		M⁽¹⁾		4,200	A	$8.05	67,050	D
Common Stock	06/29/2026		S⁽¹⁾		2,300	D	$35.1242⁽²⁾	56,450	D
Common Stock	06/29/2026		S⁽¹⁾		8,300	D	$35.0491⁽³⁾	58,750	D
Common Stock	06/30/2026		M⁽¹⁾		2,972	A	$2.59	61,722	D
Common Stock	06/30/2026		M⁽¹⁾		24,900	A	$8.05	86,622	D
Common Stock	06/30/2026		S⁽¹⁾		27,872	D	$35.4797⁽⁴⁾	58,750	D
Common Stock	06/29/2026		S⁽⁵⁾		6,997	D	$35.0481⁽⁶⁾	124,672	I	By GrayMatters Consulting BVBA⁽⁷⁾
Common Stock	06/30/2026		S⁽⁵⁾		30,703	D	$35.4896⁽⁸⁾	93,969	I	By GrayMatters Consulting BVBA⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.05	06/29/2026		M⁽¹⁾			4,200	⁽⁹⁾	04/06/2033	Common Stock	4,200	$0	69,900	D
Stock Option (Right to Buy)	$8.05	06/30/2026		M⁽¹⁾			24,900	⁽⁹⁾	04/06/2033	Common Stock	24,900	$0	45,000	D
Stock Option (Right to Buy)	$2.59	06/29/2026		M⁽¹⁾			1,400	⁽¹⁰⁾	01/01/2030	Common Stock	1,400	$0	7,072	D
Stock Option (Right to Buy)	$2.59	06/29/2026		M⁽¹⁾			4,100	⁽¹⁰⁾	01/01/2030	Common Stock	4,100	$0	2,972	D
Stock Option (Right to Buy)	$2.59	06/30/2026		M⁽¹⁾			2,972	⁽¹⁰⁾	01/01/2030	Common Stock	2,972	$0	0	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

5. This is a scheduled sale from 10b5-1 trading plan.

6. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

7. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

8. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

9. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

10. 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Pharvaris (PHVS) executive Anne Lesage report?

Anne Lesage reported exercising Pharvaris stock options to acquire 37,572 common shares and selling 76,172 shares in open-market trades. The filing describes these as cashless exercises and sales executed under a pre-arranged Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares does Anne Lesage hold after the Form 4 transactions?

After the reported transactions, Anne Lesage holds 58,750 Pharvaris common shares directly and 93,969 shares indirectly. The indirect holdings are through GrayMatters Consulting B.V., an entity that the filing states is controlled by Dr. Lesage.

Were the Pharvaris (PHVS) insider sales by Anne Lesage pre-planned?

Yes. Footnotes state the transactions were conducted under a Rule 10b5-1 trading plan. This indicates the exercises and related share sales were scheduled in advance rather than timed in response to short-term market developments or new company information.

At what prices did Anne Lesage sell Pharvaris (PHVS) shares in the Form 4?

The reported sale prices are weighted averages around $35 per share, with ranges from $35.00 up to between $35.30 and $35.86. The filing notes multiple trades per day and offers to provide detailed price breakdowns upon request.

What were the strike prices of the Pharvaris (PHVS) options exercised by Anne Lesage?

The stock options exercised had strike prices of $8.05 and $2.59 per share. The filing also notes vesting schedules, with 25% vesting on specific dates and the remainder vesting in equal monthly installments over 48 months.